摘要
目的观察重组人白介素-11(Ⅰ)治疗急性白血病化疗后血小板减少的疗效及安全性。方法 68例急性白血病患者强化治疗后出现血小板减少,分为治疗组35例,对照组33例。治疗组使用重组人白介素-11(Ⅰ)治疗,25μg/kg.d皮下注射,直至血小板连续2 d>50×109/L或>100×109/L。对照组不使用任何升血小板药物。结果治疗组血小板减少持续时间缩短,血小板输注量减少,血小板绝对值较对照组高,差异有显著性。主要不良反应为乏力、头痛、肌痛和浮肿。结论重组人白介素-11(Ⅰ)治疗急性白血病化疗后血小板减少疗效显著,且不良反应轻微,值得推广。
【Objective】To observe the effectiveness and safety of recombinant human interleukin-11（Ⅰ） in the treatment of chemotherapy induced thrombocytopenia in patients with acute leukemia.【Methods】Sixty-eight patients with chemotherapy induced thrombocytopenia after intensive treatment of acute leukemia were divided into treatment group including thirty-five patients and control group including thirty-three patients.Patients in treatment group were given subcutaneous injection of recombinant human interleukin-11（Ⅰ） at the dose of 25 μg/kg.d.Drug withdrawal was conducted after platelet count being on two consecutive days than 50×10^ 9 /L or higher than 100×10^9/ L.Patients in control group were not use any elevating platelet drugs.【Results】In treatment group,the thrombocytopenia duration was shortened;the platelet transfusion volume was reduced;the platelet absolute value was higher than the control group.The difference was statistically significant.The main ADR were fatigue,headache,muscle pain,dropsy.【Conclusion】Recombinant human interleukin 11（Ⅰ） is effective in the treatment group of chemotherapy induced thrombocytopenia in patients with acute leukemia and its adverse reactions are slight.It is worth promoting.
出处
《中国现代医学杂志》
CAS
CSCD
北大核心
2012年第30期96-98,共3页
China Journal of Modern Medicine
